SDV2102
/ Syndivia
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 26, 2025
Preclinical evaluation of SDV2102, a novel PSMA-targeting DAR1 ADC for mCRPC treatment
(AACR 2025)
- "SDV2102 achieved a therapeutic index of 38, representing a substantial safety margin. These preclinical results support the advancement of SDV2102 into clinical trials as a promising therapeutic candidate for the treatment of mCRPC."
Preclinical • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • FOLH1
1 to 1
Of
1
Go to page
1